(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.96%.
Vtv Therapeutics's earnings in 2026 is -$23,470,000.On average, 7 Wall Street analysts forecast VTVT's earnings for 2026 to be -$17,312,315, with the lowest VTVT earnings forecast at -$25,239,545, and the highest VTVT earnings forecast at -$12,032,614. On average, 7 Wall Street analysts forecast VTVT's earnings for 2027 to be -$18,549,640, with the lowest VTVT earnings forecast at -$34,617,541, and the highest VTVT earnings forecast at -$12,487,455.
In 2028, VTVT is forecast to generate -$12,733,187 in earnings, with the lowest earnings forecast at -$14,587,994 and the highest earnings forecast at -$10,585,392.